PCVX Description — Vaxcyte Inc

Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.

Company Name: 
Vaxcyte Inc
Number of ETFs Holding PCVX: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   PCVX Weight   PCVX Amount 
 VTI   0.01%   $81,748,849         
 VB   0.06%   $69,466,274         
 XBI   0.99%   $65,150,375         
 IWM   0.12%   $60,835,188         
 VBK   0.14%   $40,094,828         
 VXF   0.04%   $31,971,762         
 IWO   0.23%   $21,021,759         
 VTWO   0.12%   $7,289,665         
 VHT   0.04%   $7,233,723         
 PTH   2.65%   $4,741,618         
List of all 29 ETFs holding PCVX »
Quotes delayed 20 minutes

Email EnvelopeFree PCVX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.86 out of 4)
72nd percentile
(ranked higher than approx. 72% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding PCVX | Vaxcyte Inc | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.